Angiodynamics Inc. (ANGO)
AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines
ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.
AngioDynamics: A Surgical Approach To Market Growth
AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call.
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago.
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
